RYTM
Rhythm Pharmaceuticals, Inc.
Stock
$92.83−0.58 (−0.62%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $240M | $190M | $130M | $77M | $24M | $3.2M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $26M | $19M | $13M | $9.3M | $2.1M | $599K | — | — | — | — | — |
| Gross profit | $214M | $170M | $117M | $68M | $22M | $2.6M | — | — | — | — | — |
| R&D | $173M | $167M | $238M | $135M | $109M | $104M | $90M | $109M | $50M | $23M | $20M |
| SG&A | $241M | $195M | $144M | $118M | $92M | $68M | $46M | $37M | $28M | $9.5M | $6.3M |
| Operating income | −$201M | −$192M | −$266M | −$184M | −$179M | −$170M | −$137M | −$146M | −$78M | −$32M | −$26M |
| Non-operating income | −$3.6M | −$4.0M | $5.2M | $243K | −$2.0M | $100M | — | — | — | — | — |
| Pretax income | −$204M | −$196M | −$260M | −$184M | −$181M | −$70M | — | — | — | — | — |
| Taxes | $1.1M | $497K | $346K | $564K | $0 | $0 | — | — | — | — | — |
| Net income | −$205M | −$197M | −$261M | −$185M | −$181M | −$70M | −$134M | −$141M | −$74M | −$34M | −$26M |
| Diluted EPS | −$3.11 | −$3.11 | −$4.34 | −$3.20 | −$3.47 | −$1.40 | −$3.04 | −$3.86 | −$2.39 | −$2.83 | −$2.85 |
| Diluted shares | — | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M | 44.1M | 36.4M | 31.0M | 13.3M | 10.2M |
| Revenue growth | — | +45.8% | +68.1% | +227.6% | +649.5% | — | — | — | — | — | — |
| Gross margin | 89.0% | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | — | — | — | — | — |
| Operating margin | −83.6% | −101.2% | −204.0% | −238.1% | −757.9% | −5,391.9% | — | — | — | — | — |
| Net margin | −85.6% | −103.6% | −200.3% | −238.5% | −766.2% | −2,207.1% | — | — | — | — | — |